Form 4: Abbott Laboratories Director Receives Equity Grant

Director Michelle Kumbier was granted 2,286 restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program.

Summary

• Director Michelle Kumbier acquired 2,286 restricted stock units (RSUs) on April 24, 2026.
• The grant was issued under the Abbott Laboratories 2026 Incentive Stock Program.
• The RSUs will be settled in common shares on a one-to-one basis upon the director's separation from service, death, or a change in control.
• Following this transaction, the director's total beneficial ownership is 18,000 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The RSU award is subject to future settlement based on the director's separation from service, death, or a change in control of the company.

Management Comments

• The award is granted under the Abbott Laboratories 2026 Incentive Stock Program.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice to ensure alignment between leadership and shareholders in the healthcare and medical device sector.

Comparison to Industry Standards

• The use of restricted stock units for director compensation is consistent with standard practices among large-cap S&P 500 healthcare companies.
• The vesting schedule tied to separation from service is a common retention and alignment mechanism for non-employee directors.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation.

Next Steps

• The director will hold the RSUs until the occurrence of a triggering event such as separation from service.

Key Dates

Keywords

Abbott Laboratories, ABT, Form 4, Insider Transaction, Equity Compensation, Director Ownership